Trials / Recruiting
RecruitingNCT06507436
The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
The Efficacy and Safety of Herombopag in Treating Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery - A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 101 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study includes Part A and Part B. Part A is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery. Part B is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy and safety of Herombopag compared to placebo in patients with chronic liver disease-related thrombocytopenia undergoing elective invasive surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Herombopag tablets | Herombopag tablets; dose 1 or dose 2, for 5 days |
| DRUG | Herombopag placebo tablets | Herombopag placebo tablets; dose 1 or dose 2, for 5 days |
Timeline
- Start date
- 2024-07-31
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-07-18
- Last updated
- 2025-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06507436. Inclusion in this directory is not an endorsement.